Axiom International Investors Boosted Its Illumina (ILMN) Position by $14.04 Million as Share Value Rose; Abbott Laboratories (ABT) Shareholder Dsm Capital Partners Increased Position

January 14, 2018 - By Kurt Siggers

Dsm Capital Partners Llc increased its stake in Abbott Laboratories (ABT) by 81.46% based on its latest 2017Q3 regulatory filing with the SEC. Dsm Capital Partners Llc bought 1.56M shares as the company’s stock declined 3.42% while stock markets rallied. The hedge fund held 3.47 million shares of the major pharmaceuticals company at the end of 2017Q3, valued at $185.02 million, up from 1.91 million at the end of the previous reported quarter. Dsm Capital Partners Llc who had been investing in Abbott Laboratories for a number of months, seems to be bullish on the $102.42B market cap company. The stock decreased 0.19% or $0.11 during the last trading session, reaching $58.84. About 6.32 million shares traded or 6.93% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since January 14, 2017 and is uptrending. It has underperformed by 0.80% the S&P500.

Axiom International Investors Llc increased its stake in Illumina Inc (ILMN) by 60.9% based on its latest 2017Q3 regulatory filing with the SEC. Axiom International Investors Llc bought 70,572 shares as the company’s stock rose 8.35% with the market. The institutional investor held 186,457 shares of the capital goods company at the end of 2017Q3, valued at $37.14M, up from 115,885 at the end of the previous reported quarter. Axiom International Investors Llc who had been investing in Illumina Inc for a number of months, seems to be bullish on the $35.73B market cap company. The stock increased 1.95% or $4.68 during the last trading session, reaching $244.72. About 975,763 shares traded or 17.23% up from the average. Illumina, Inc. (NASDAQ:ILMN) has risen 28.24% since January 14, 2017 and is uptrending. It has outperformed by 11.54% the S&P500.

Among 28 analysts covering Illumina Inc (NASDAQ:ILMN), 17 have Buy rating, 1 Sell and 10 Hold. Therefore 61% are positive. Illumina Inc had 85 analyst reports since July 22, 2015 according to SRatingsIntel. Piper Jaffray maintained Illumina, Inc. (NASDAQ:ILMN) rating on Tuesday, October 6. Piper Jaffray has “Overweight” rating and $220 target. The stock has “Buy” rating by Canaccord Genuity on Monday, August 7. Morgan Stanley maintained the stock with “Equal-Weight” rating in Tuesday, April 19 report. The rating was maintained by Cowen & Co with “Buy” on Wednesday, December 20. As per Tuesday, April 19, the company rating was downgraded by Bank of America. The stock of Illumina, Inc. (NASDAQ:ILMN) earned “Hold” rating by Canaccord Genuity on Tuesday, October 11. The rating was maintained by Cowen & Co with “Outperform” on Tuesday, April 19. Bank of America maintained it with “Buy” rating and $240 target in Wednesday, October 25 report. The firm earned “Market Perform” rating on Friday, January 5 by William Blair. The rating was maintained by Goldman Sachs on Tuesday, October 6 with “Neutral”.

Axiom International Investors Llc, which manages about $10.22 billion and $4.45B US Long portfolio, decreased its stake in Ishares Tr (INDA) by 93,170 shares to 1.85 million shares, valued at $60.72M in 2017Q3, according to the filing. It also reduced its holding in Fireeye Inc (NASDAQ:FEYE) by 51,512 shares in the quarter, leaving it with 172,371 shares, and cut its stake in Mohawk Inds Inc (NYSE:MHK).

Since August 1, 2017, it had 0 buys, and 23 selling transactions for $47.02 million activity. Dadswell Charles sold 1,609 shares worth $316,973. Another trade for 2,000 shares valued at $411,857 was sold by Stapley Marc. $2.11M worth of Illumina, Inc. (NASDAQ:ILMN) was sold by EASTHAM KARIN. On Thursday, September 7 the insider Ronaghi Mostafa sold $4.20M. Another trade for 9,729 shares valued at $2.06M was sold by Van Oene Mark. Bouchard Michel also sold $1.09M worth of Illumina, Inc. (NASDAQ:ILMN) on Wednesday, August 30.

Investors sentiment decreased to 1.1 in 2017 Q3. Its down 0.24, from 1.34 in 2017Q2. It is negative, as 33 investors sold ILMN shares while 167 reduced holdings. 55 funds opened positions while 165 raised stakes. 131.54 million shares or 1.36% less from 133.36 million shares in 2017Q2 were reported. First Mercantile Trust holds 2,232 shares or 0.08% of its portfolio. Vanguard Gp has invested 0.09% in Illumina, Inc. (NASDAQ:ILMN). Pacad Investment Limited has 1,300 shares for 0.06% of their portfolio. The New York-based Qs Limited Liability Corp has invested 0.01% in Illumina, Inc. (NASDAQ:ILMN). 684,955 are owned by Legal General Gp Public Limited Co. Sands Cap Mngmt Limited Liability stated it has 2.94% in Illumina, Inc. (NASDAQ:ILMN). American Research And has 0.02% invested in Illumina, Inc. (NASDAQ:ILMN) for 350 shares. Smith Salley, North Carolina-based fund reported 1,954 shares. Cubist Systematic Strategies Ltd Com reported 0.05% of its portfolio in Illumina, Inc. (NASDAQ:ILMN). Eagle Asset Management owns 206,558 shares. Kornitzer Ks holds 0.04% or 11,937 shares in its portfolio. Renaissance Tech Limited Liability Corp owns 133,218 shares. Washington Mgmt Inc reported 1,400 shares. Korea Invest reported 0.02% in Illumina, Inc. (NASDAQ:ILMN). Perigon Wealth Management Ltd Co reported 4,377 shares.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 92 analyst reports since July 24, 2015 according to SRatingsIntel. BMO Capital Markets maintained it with “Hold” rating and $53.0 target in Monday, October 2 report. The rating was initiated by Citigroup with “Hold” on Thursday, August 17. The rating was maintained by JP Morgan on Friday, October 6 with “Neutral”. Barclays Capital maintained the stock with “Overweight” rating in Thursday, October 19 report. UBS initiated the stock with “Neutral” rating in Tuesday, September 22 report. The rating was maintained by Jefferies on Thursday, August 4 with “Buy”. On Thursday, October 19 the stock rating was maintained by Citigroup with “Neutral”. On Friday, January 29 the stock rating was maintained by RBC Capital Markets with “Outperform”. The firm has “Buy” rating given on Wednesday, October 18 by Jefferies. Jefferies maintained Abbott Laboratories (NYSE:ABT) rating on Tuesday, October 10. Jefferies has “Buy” rating and $58.0 target.

Since August 1, 2017, it had 0 buys, and 6 sales for $22.86 million activity. Another trade for 196,550 shares valued at $9.73 million was sold by Fussell Stephen R. The insider Contreras Jaime sold 52,700 shares worth $2.74M. Bracken Sharon J had sold 2,000 shares worth $98,323.

Investors sentiment decreased to 0.87 in Q3 2017. Its down 0.01, from 0.88 in 2017Q2. It dived, as 47 investors sold ABT shares while 563 reduced holdings. 111 funds opened positions while 421 raised stakes. 1.21 billion shares or 0.79% less from 1.22 billion shares in 2017Q2 were reported. Norman Fields Gottscho Capital Mgmt Limited Liability Com invested 0.42% of its portfolio in Abbott Laboratories (NYSE:ABT). Kcm Inv Advisors Ltd Co accumulated 210,531 shares. Cornerstone Capital Mngmt Holdg Lc accumulated 363,312 shares. Fundx Invest Grp Ltd Com accumulated 0.43% or 19,000 shares. Pennsylvania-based Janney Montgomery Scott Limited Company has invested 0.23% in Abbott Laboratories (NYSE:ABT). 1,833 were reported by Central Bancorporation And Tru Commerce. Sunbelt Secs Incorporated holds 0.5% or 8,968 shares. Moreover, Lodestar Counsel Limited Liability Company Il has 1.81% invested in Abbott Laboratories (NYSE:ABT). Mairs Power Incorporated accumulated 2.93% or 4.57M shares. Koch Industries holds 0.11% or 8,420 shares in its portfolio. Alpha Cubed Invs Limited Company stated it has 17,832 shares or 0.14% of all its holdings. 16,603 were accumulated by Annex Advisory Services Limited Liability Corporation. M&T National Bank holds 0.24% or 843,062 shares in its portfolio. Cap One Association holds 0.11% in Abbott Laboratories (NYSE:ABT) or 30,629 shares. Regal Inv Limited Company reported 5,840 shares or 0.07% of all its holdings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: